Evidence map›Paper›PMID 37191437›Full record

ArticleCancer discovery2023

Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia.

Winnie L Kan, Urmi Dhagat, Kerstin B Kaufmann, Timothy R Hercus, Tracy L Nero, Andy G X Zeng, John Toubia, Emma F Barry, Sophie E Broughton, Guillermo A Gomez and 16 more

Open access · hybridAbstract read
In one paragraph

Article in Cancer discovery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 8 institutions in 4 countries.

Winnie L Kan *Cytokine Receptor Laboratory, Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.ORCID 0000-0002-5844-7644
Urmi Dhagat *Australian Cancer Research Foundation Rational Drug Discovery Centre, St. Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia.ORCID 0000-0002-5650-5767
Kerstin B Kaufmann *Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID 0000-0001-5013-6123
Timothy R Hercus *Cytokine Receptor Laboratory, Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.ORCID 0000-0001-5290-9206
Tracy L Nero *Australian Cancer Research Foundation Rational Drug Discovery Centre, St. Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia.ORCID 0000-0002-3393-1843
Andy G X Zeng *Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID 0000-0002-3223-6400
John Toubia *Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.ORCID 0000-0002-5135-6504
Emma F BarryCytokine Receptor Laboratory, Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.ORCID 0000-0003-2742-5650
Sophie E BroughtonAustralian Cancer Research Foundation Rational Drug Discovery Centre, St. Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia.ORCID 0000-0003-1358-5063
Guillermo A GomezCytokine Receptor Laboratory, Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.ORCID 0000-0002-0494-2404
Brooks A BenardDivision of Hematology, Department of Medicine, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California.ORCID 0000-0001-7154-744X
Mara DottoreCytokine Receptor Laboratory, Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.ORCID 0000-0002-0254-6598
Karen S Cheung Tung ShingAustralian Cancer Research Foundation Rational Drug Discovery Centre, St. Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia.ORCID 0000-0002-3817-0860
Héléna BoutzenPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID 0000-0002-7624-9326
Saumya E SamaraweeraCentre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.ORCID 0000-0002-9619-0624
Kaylene J SimpsonVictorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0001-9136-1781
Liqing JinPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID 0009-0009-9639-4836
Gregory J GoodallCentre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.ORCID 0000-0003-1294-0692
C Glenn BegleyBegley Biotech Consulting, Wallington, Victoria, Australia.ORCID 0000-0003-2419-6215
Daniel ThomasDivision of Hematology, Department of Medicine, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-0837-1231
Paul G EkertTranslational Tumour Biology Group, Children's Cancer Institute, Lowy Cancer Centre, University of New South Wales, Randwick, New South Wales, Australia.ORCID 0000-0002-2976-8617
Denis TvorogovCytokine Receptor Laboratory, Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.ORCID 0000-0002-2009-1347
Richard J D'AndreaCentre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.ORCID 0000-0002-4915-4612
John E DickPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID 0000-0002-9527-8317
Michael W ParkerAustralian Cancer Research Foundation Rational Drug Discovery Centre, St. Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia.ORCID 0000-0002-3101-1138
Angel F LopezCytokine Receptor Laboratory, Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.ORCID 0000-0001-7430-0135
Centre for Cancer Biology · AUAustralian Cancer Research Foundation · AUPrincess Margaret Cancer Centre · CACalifornia Institute for Regenerative Medicine · USUniversity of Toronto · CAFishwell Consulting (Australia) · AUPeter MacCallum Cancer Centre · AURoyal Children's Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leukemia stem cells (LSC) possess distinct self-renewal and arrested differentiation properties that are responsible for disease emergence, therapy failure, and recurrence in acute myeloid leukemia (AML). Despite AML displaying extensive biological and clinical heterogeneity, LSC with high interleukin-3 receptor (IL3R) levels are a constant yet puzzling feature, as this receptor lacks tyrosine kinase activity. Here, we show that the heterodimeric IL3Rα/βc receptor assembles into hexamers and dodecamers through a unique interface in the 3D structure, where high IL3Rα/βc ratios bias hexamer formation. Importantly, receptor stoichiometry is clinically relevant as it varies across the individual cells in the AML hierarchy, in which high IL3Rα/βc ratios in LSCs drive hexamer-mediated stemness programs and poor patient survival, while low ratios mediate differentiation. Our study establishes a new paradigm in which alternative cytokine receptor stoichiometries differentially regulate cell fate, a signaling mechanism that may be generalizable to other transformed cellular hierarchies and of potential therapeutic significance. SIGNIFICANCE: Stemness is a hallmark of many cancers and is largely responsible for disease emergence, progression, and relapse. Our finding that clinically significant stemness programs in AML are directly regulated by different stoichiometries of cytokine receptors represents a hitherto unexplained mechanism underlying cell-fate decisions in cancer stem cell hierarchies. This article is highlighted in the In This Issue feature, p. 1749.

Indexed as

Leukemia, Myeloid, AcuteReceptors, CytokineCell ProliferationHumansNeoplastic Stem CellsPhosphorylationSignal TransductionReceptors, Cytokine

Identifiers

PMID37191437
PMCPMC10401075
OpenAlexW4376641408

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.